Adoption of rimegepant in Denmark: a register-based study on uptake, prescribing patterns and initiator characteristics.

ABSTRACT:

Background

Rimegepant, an oral calcitonin gene-related peptide (CGRP) receptor antagonist, is the first drug within its class approved for both acute and preventive treatment of migraine. This study examines its uptake in Denmark.

Methods

Using nationwide healthcare registry data, we analyze trends in rimegepant prescriptions from its introduction in October 2022 to December 2024. Parameters assessed include demographic and clinical characteristics of users, temporal trends in drug use, treatment adherence, and concomitant use of other migraine therapies.

Results

By December 2024, over 140,000 defined daily doses (DDDs) of rimegepant had been dispensed in Denmark, primarily among females (88%), with a users' median age of 45 years. Most initiators had prior experience

SUBMITTER: Pellesi L 

PROVIDER: S-EPMC12007292 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature